For prostate cancer, another selective A2AR antagonist, AZD4635, is being used in phase 2 open-label modular study in combination with oleclumab (MEDI9447), which targets CD73/5′-nucleotidase, with durvalumab (MEDI4736), which targets PD-1 protein, or with both antibodies (CTg Identifier: NCT04089553). The gene discussed is NT5E; the disease is prostate cancer.